NCT01968668 - Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 28, 2013

Primary Completion Date

October 9, 2014

Study Completion Date

November 7, 2014

Conditions

Diabetic Nephropathies

Interventions

DRUG

BAY94-8862

1.25 mg BAY94-8862 tablet once daily in the morning

DRUG

BAY94-8862

2.5 mg BAY94-8862 tablet once daily in the morning

DRUG

BAY94-8862

5 mg BAY94-8862 tablet once daily in the morning

DRUG

BAY94-8862

7.5 mg BAY94-8862 tablet once daily in the morning

DRUG

BAY94-8862

10 mg BAY94-8862 tablet once daily in the morning

DRUG

Placebo

Placebo tablet once daily in the morning

DRUG

BAY 94-8862

15 mg BAY 94-8862 tablet once daily in the morning

DRUG

BAY 94-8862

20 mg BAY 94-8862 tablet once daily in the morning

Trial Locations (16)

456-0058

Nagoya

466-0815

Nagoya

793-0027

Saijō

830-8522

Kurume

830-8543

Kurume

080-0848

Obihiro

660-8550

Amagasaki

306-0232

Koga

300-0835

Tsuchiura

305-0812

Tsukuba

920-0293

Kahoku-gun

762-0007

Sakaidechō

598-8577

Izumisano

581-0011

Yao

125-0054

Katsushika-ku

530-0001

Osaka